天津龙济医院的服务好吗天津龙济医院泌尿科医院,天津龙济割包皮挂哪个科,武清区龙济位置在哪里,天津市龙济泌尿外科做包皮手术费用,天津龙济男人医院怎么样,天津武清龙济医院有没有泌尿科,天津市龙济泌尿外科男子医院地址

While hundreds of families wait in agony to learn the fate of missing loved ones, officials gave a gut-wrenching forecast on the fate of California's Camp Fire:It's not even halfway done burning yet.Since the Camp Fire erupted 10 days ago in Butte County, it has killed 77 people, destroyed more than 9,700 homes and torched an area the size of Chicago.But the blaze probably won't be fully contained until November 30, according to Cal Fire, the state's forestry and fire protection agency."It is overwhelming, I don't have any word to describe it," Butte County Sheriff and Coroner Kory Honea said. "This is unprecedented. No one has had to deal with this magnitude that caused so much destruction and regrettably so much death."Meanwhile, displaced residents are in limbo. Many are in Chico, Butte County's most populous city, about 15 miles from ground zero of the disaster, the town of Paradise.Some evacuees are staying with friends and family. Others are in a tent city in a Walmart parking lot. On Sunday, those seeking a place to grieve trickled into the First Christian Church of Chico for a candlelight vigil.A sign in the church set an intention for the hourslong open memorial: "We will rise from the ashes."The Camp Fire is already the deadliest and most destructive wildfire in California history. And with 993 people still unaccounted for, officials fear the death toll could keep rising.Crews are combing the remnants of houses where all evidence of life has been wiped out by flames. Many of the searchers have lost their own homes and are looking for the remains of their neighbors.While the search for the dead and missing continues, thousands of firefighters are trying to control the blaze. As of late Sunday, the Camp Fire had seared 150,000 acres and was 65% contained. 1826

What to keep in mind with credit card bill payments (READ)Tips on handling your credit cards amid virus outbreak (READ)Help available for renters, homeowners struggling to pay for housing during pandemic (READ)3 ways credit cards can help you ride out a crisis (READ)SAN DIEGO (KGTV) -- Tens of thousands of people in California are being sued for not paying their credit card bills and other types of loan payments. The lawsuits are what's known as rule 3.740 collection cases."A lot of worrying after that, like oh my god, what am I going to do," said Chris Madden. "Stressed out now and just didn't need it."In February, Madden was served with a lawsuit from a debt collection company.During an interview with 10 News that month Madden said he needed to borrow money a few years ago to keep his car. He turned to a lender that could get him money quickly."I figured it was going to be a high-interest rate, like 22% or something," he said. "I started making the payments on it, and then I found out more about it."Madden admits he didn't do a great job getting all the details when he took the money, saying the interest rate wasn't clear. When he finally did look at the fine print, he saw the interest rate was 135%. Court documents show a ,000 loan turned into ,000 owed."They were threatening to take any assets that I have, garnish my wages," Madden said.Madden said he stopped paying. He's being sued by a debt buyer under what's known as a rule 3.740 collections case.According to the 2020 California Rules of Court, "Collections case" means an action for recovery of money owed in a sum stated to be certain that is not more than ,000, exclusive of interest and attorney fees, arising from a transaction in which property, services, or money was acquired on credit."Team 10 discovered a 157% increase in the number of rule 3.740 collections lawsuits filed in San Diego County court from 2015 to 2019. 1927

WESTFIELD, New Jersey — A New Jersey family says it was scared away from its home after a series of cryptic and threatening letters from someone known as "The Watcher."The family is now speaking out about its own real-life horror movie.Derek and Maria Broaddus were too spooked to ever move into their .3 million dream home in Westfield, New Jersey.They spoke with New York magazine in their first public interview after the scary ordeal that went on for years.The first letter arrived one night in June 2014. Derek had just finished an evening of painting his new six-bedroom home at 657 Boulevard.Dearest new neighbor at 657 Boulevard, 647

White House officials and House Democrats said Friday they’re no closer to a deal with on a stimulus package, a week after extended unemployment benefits expired.While the White House said they believe a compromise can be made on some issues, the two sides remain far apart on funding state and local governments. Many states and municipalities are struggling due to decreased revenues and increased costs amid the pandemic.There is also disagreement among the parties, including Senate Republicans, on unemployment supplements as unemployment figures remain over 10%. From April into July, unemployed workers received an additional 0 unemployment supplement on top of standard unemployment benefits. But many Republicans grumbled that the supplement gave incentive for workers to stay home amid the pandemic.Generally, however, if an employer calls an employee back to work, they're no longer eligible for unemployment benefits.Treasury Secretary Steven Mnuchin told reporters on Capitol Hill Friday that he is going to recommend executive orders addressing student loan payments, evictions and unemployment supplements. Currently, federal student loan payments are frozen into October. Also, protection ended last week on evictions.President Donald Trump told reporters late Friday that he plans on signing the order "by the end of the week." But Trump said he expects there will be legal challenges to his order. Mnuchin and White House Chief of Staff Mark Meadows said that there is broad agreement on some issues, such as funding for schools to safely operate amid the pandemic. Previously, the sides also said there is agreement on providing Americans with ,200 stimulus checks for the second time this year. But Mnuchin and Meadows pointed the finger at House Democrats for not compromising on the unresolved issues.“Just to hear the comments from Senator Schumer and Speaker Pelosi saying they “want a deal” when behind closed doors, their actions do not indicate the same thing,” Meadows said.Meanwhile, Democrats pointed the finger back at the White House for not reaching a compromise.While the White House suggested that it would be okay with a partial stimulus package, Democrats are calling for a more comprehensive bill.“We’re asking them to be fair, to meet us in the middle, not to have a my way or the highway attitude, which they seem to have,” Senate Minority Leader Chuck Schumer said. “We can really get this done, because there are some areas where we didn’t come to an agreement on many things, but we narrowed our differences.”Both the House and Senate have adjourned for the weekend. 2622

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919